agonistas glp 1 glp-1_analogs [TUSOM GLP-1 receptor agonists for individualized
Description
To qualify for the Medicare GLP-1 Bridge program, you must: - Have Medicare Part D - Meet specific BMI and health condition criteria that a doctor must document, mainly: - BMI of 35 or higher, or - BMI of 30-34.99 and have diastolic heart failure, uncontrolled high blood pressure, chronic kidney disease at stage 3a or higher, prediabetes, a previous heart attack or stroke, blocked arteries in your legs or arms with symptoms, or - BMI of 30 or higher along with certain health conditions, including heart failure, uncontrolled high blood pressure, or chronic kidney disease, or - BMI between 27-29.99 and have prediabetes, a previous heart attack or stroke, blocked arteries in your legs or arms with symptoms

GLP-1 drugs are suspected to raise the risk of each

The study also found that the longer subjects were treated with these medications, the greater their risk of developing wet AMD

Oral GLP-1 weight loss medication Orfoglipron (Eli Lilly) is nearing an FDA decision with available expect mid-2026 Clinical trials show meaningful results: 12-16% 1,2 average weight loss, which is slightly less than injectables Side effects are similar: mostly gastrointestinal, such as nausea or diarrhea, typically improving over 23 months

2015 Dec;13(10):423444

It may also inhibit the neurons in the ARC that contain POMC-derivative alpha-MSH that mediate the anorexigenic effect in the PVN (9, 16, 18)
